Objective While there are several trials that support the efficacy of various drugs for migraine
prophylaxis against placebo, there is limited evidence addressing the comparative safety …

Abstract Purpose of Review: This article reviews the evidence base for the preventive
treatment of migraine. Recent Findings: Evidence-based guidelines for the preventive …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Background Quality clinical trials form an essential part of the evidence base for the
treatment of headache disorders. In 1991, the International Headache Society Clinical Trials …

Clinical trials are a key component of the evidence base for the treatment of headache
disorders. In 1991, the International Headache Society Clinical Trials Standing Committee …

International Headache Society Clinical Trials Subcommittee members: Peer Tfelt-Hansen
(chairman)(Denmark) 1, Julio Pascual (vice-chairman)(Spain) 2, Nabih Ramadan (vice …

Background National and international guidelines recommend stop** migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6–12 months of successful …

Migräne ist mit einer Punktprävalenz von 20% bei Frauen und 8% bei Männern eine häufige
Erkrankung. Daher sind Leitlinien für die Behandlung von Migräneattacken sowie die …

Introduction Migraine prophylactic therapy has changed over recent years with the
development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene …

Migraine is a common and disabling brain disorder with a strong inherited component.
Because patients with migraine have severe and disabling attacks usually of headache with …